Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
Meiji Seika Pharma on September 30 launched its self-amplifying mRNA COVID-19 vaccine Kostaive in Japan, which will be used under the government’s inoculation program for the 2024/2025 fall-winter season. A JN.1-targeted version of Kostaive that hit the market was approved…
To read the full story
Related Article
- COVID Shot Kostaive Lands EU Approval, 1st Nod Outside Japan
February 19, 2025
- Domestic Sites Approved for Meiji’s COVID Vaccine Kostaive
February 4, 2025
- Japan Approves Meiji’s JN.1-Directed COVID-19 Vaccine
September 13, 2024
BUSINESS
- J&J Submits Information Disclosure Requests to Japan Govt over Off-Year Revision
March 26, 2025
- Eisai Eyes Up to 280 Billion Yen Sales for Leqembi in FY2027: CEO
March 26, 2025
- Kaken Snags Japan Rights to Alumis’ Dermatology Asset
March 26, 2025
- MEDRx/DWTI Make 4th Attempt to Seek US Nod for Lidocaine Patch
March 26, 2025
- FRONTEO’s AI Engine Can Help Unearth Drug Targets, Predict Odds of Success: CTO
March 25, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…